Veress Needles, as a type of medical device that directly comes into contact with the human body, all major manufacturers worldwide must establish a comprehensive compliance quality management system and pass rigorous international and domestic certifications in order to gain market access globally. The ISO13485 system, FDA certification, CE MDR certification, and NMPA certification have become the core thresholds for manufacturers to enter the international market and conduct domestic sales. Leading manufacturers rely on their mature compliance strategies to seize the global market, while smaller manufacturers face development bottlenecks due to their compliance shortcomings.

ISO13485 is a universal quality management standard for the global medical device industry and is also the core guideline for production and quality control of Veress Needles manufacturers. Leading international manufacturers such as BD, Teleflex, and Storz have established comprehensive ISO13485 systems, implementing standardized control throughout the entire process from raw material procurement, production processing, factory inspection, packaging sterilization, to after-sales traceability. Raw material suppliers must provide material testing reports, and each production process is supervised by dedicated quality inspectors. The finished products undergo air tightness, size, and biocompatibility tests to ensure they meet global standards, laying the foundation for subsequent international certifications. Domestic leading manufacturers such as Weigao Group and Hangzhou Nusen Medical have benchmarked against international standards and established a localized ISO13485 system, introducing a digital traceability system to achieve full-process traceability of each Veress Needle from production to use, thereby enhancing product compliance and credibility.

The market access certification requirements vary among different countries and regions, becoming a core barrier for manufacturers to expand their global market presence. To enter the US market, manufacturers need to obtain FDA 510(k) certification. They must submit product performance data, clinical comparison data, and biocompatibility reports to prove that the product is substantially equivalent to already legally marketed products. International brands like BD, with their accumulated clinical data over the years, easily pass the FDA certification and smoothly enter the US market. When domestic manufacturers enter the US market, due to insufficient clinical data accumulation, the certification process is longer and they need to invest a large amount of funds in conducting clinical trials to increase the certification pass rate.

The EU market requires manufacturers to obtain CE MDR certification, which is more stringent than the previous certification standards. It demands that manufacturers complete technical documents, risk management documents, and clinical evidence documents for their products. Small and medium-sized manufacturers, due to their lack of R&D capabilities, find it difficult to meet the MDR certification requirements and are forced to withdraw from the EU market. Headline manufacturers, on the other hand, have made early preparations, optimized their product risk management systems, and accumulated clinical real-world data, successfully obtaining CE certification and seizing the EU minimally invasive device market. The domestic market is regulated by NMPA. Veress Needles, as a type 3 device, has a long registration period and strict requirements. International manufacturers quickly obtain approval by leveraging their brand advantages, while domestic manufacturers rely on their local advantages, familiar with the NMPA registration process, to shorten the registration period and achieve rapid product launch.

The construction of compliance systems is not only a market entry threshold, but also a guarantee for the clinical safety of products. Leading manufacturers have significantly reduced the incidence of clinical adverse events of their products through strict compliance control, thereby enhancing their brand reputation. However, some small and medium-sized manufacturers, in an effort to cut costs, simplify the quality inspection process and skip certain certification steps, have left products with potential safety hazards. These products are highly prone to causing medical accidents and are subject to regulatory penalties.

With the increasingly strict global regulation of medical devices, manufacturers of Veress Needles must continuously improve their compliance systems. International manufacturers are deeply engaged in obtaining global certifications and expanding their overseas market presence; domestic manufacturers, based on NMPA certification, are benchmarking against FDA and CE standards, accumulating international certification experience, and gradually establishing a presence in overseas markets. In the future, compliance capabilities will become the core competitiveness of manufacturers. Only by adhering to the quality bottom line and improving the compliance system can manufacturers in the Veress Needles industry continue to develop steadily and promote the standardized upgrade of the global minimally invasive surgical device industry.